PDCD1 and non-small cell lung carcinoma: In this line, Caetano et al. [202] explored the combination of an anti-PD-1 antibody with a MER proto-oncogene tyrosine kinase inhibitor (MerTKI) and three 12 Gy doses of radiation in a murine flank model of NSCLC and pancreatic cancer.